Michael Rytting

6.3k total citations · 1 hit paper
96 papers, 4.2k citations indexed

About

Michael Rytting is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Genetics. According to data from OpenAlex, Michael Rytting has authored 96 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Public Health, Environmental and Occupational Health, 40 papers in Hematology and 35 papers in Genetics. Recurrent topics in Michael Rytting's work include Acute Lymphoblastic Leukemia research (59 papers), Acute Myeloid Leukemia Research (28 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Michael Rytting is often cited by papers focused on Acute Lymphoblastic Leukemia research (59 papers), Acute Myeloid Leukemia Research (28 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Michael Rytting collaborates with scholars based in United States, Italy and Canada. Michael Rytting's co-authors include Jörge E. Cortes, Nicholas J. Short, Hagop M. Kantarjian, Elias Jabbour, Farhad Ravandi, Susan O’Brien, Deborah A. Thomas, Guillermo Garcia‐Manero, Stefan Faderl and Sima Jeha and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Rytting

93 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acute myeloid leukaemia

2018 544 citations Nicholas J. Short, Michael Rytting et al. The Lancet profile →

Peers

Countries citing papers authored by Michael Rytting

Since Specialization

Citations

This map shows the geographic impact of Michael Rytting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Rytting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Rytting more than expected).

Fields of papers citing papers by Michael Rytting

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Rytting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Rytting. The network helps show where Michael Rytting may publish in the future.

Co-authorship network of co-authors of Michael Rytting

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Rytting. A scholar is included among the top collaborators of Michael Rytting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Rytting. Michael Rytting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia 2021 ·Leukemia ·Francesco Paolo Tambaro, Harjeet Singh, (unknown), Michael Rytting, Kris M. Mahadeo, Philip A. Thompson, Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Guillermo Garcia‐Manero, Tim Hon Man Chan, Rutul R. Shah, William G. Wierda	123
2	Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives 2021 ·Pediatric Drugs ·(unknown), (unknown), (unknown), Jitesh D. Kawedia, Michael Rytting, Branko Cuglievan	7
3	Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib 2019 ·Blood ·Yuya Sasaki, Nicholas J. Short, Hagop M. Kantarjian, Rebecca Garris, Nitin Jain, Koji Sasaki, Farhad Ravandi, Marina Konopleva, Michael Rytting, Guillermo Garcia‐Manero, Latasha Little, Curtis Gumbs, Li Zhao, P. Andrew Futreal, Feng Wang, Koichi Takahashi, Elias Jabbour	2
4	Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Guillaume Richard‐Carpentier, Elias Jabbour, Nicholas J. Short, Caitlin R. Rausch, (unknown), Prithviraj Bose, Musa Yılmaz, Nitin Jain, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Michael Rytting, Partow Kebriaei, Marina Konopleva, Hagop M. Kantarjian, Farhad Ravandi	84
5	Acute myeloid leukaemia breakdown → 2018 ·The Lancet ·Nicholas J. Short, Michael Rytting, Jörge E. Cortes	544
6	Acute myeloid leukaemia masquerading as a primary CNS tumour 2017 ·BMJ Case Reports ·Branko Cuglievan, Brian A. Menegaz, Sofía Garcés, Michael Rytting	3
7	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 2015 ·Haematologica ·Naval Daver, Deborah A. Thomas, Farhad Ravandi, Jörge E. Cortes, Rebecca Garris, Elias Jabbour, Guillermo Garcia‐Manero, Gautam Borthakur, Tapan M. Kadia, Michael Rytting, Marina Konopleva, Hagop M. Kantarjian, Susan O’Brien	171
8	Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial 2015 ·Journal of Neuro-Oncology ·David I. Sandberg, Michael Rytting, Wafik Zaky, Marcia Kerr, Leena Ketonen, Uma Kundu, Bartlett D. Moore, Grace Meijuan Yang, Ping Hou, Clark Sitton, Laurence J.N. Cooper, Vidya Gopalakrishnan, Dean A. Lee, Peter F. Thall, Soumen Khatua	19
9	An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN) 2015 ·Journal of Neuro-Oncology ·Mariko DeWire, Maryam Fouladi, David C. Turner, Cynthia Wetmore, Cynthia Hawkins, Carmen Jacob, Ying Yuan, Diane Liu, Stewart Goldman, Paul G. Fisher, Michael Rytting, Éric Bouffet, Yasmin Khakoo, Eugene Hwang, Nicholas K. Foreman, Clinton F. Stewart, Mark R. Gilbert, Richard J. Gilbertson, Amar Gajjar	43
10	Asparaginase in Acute Lymphoblastic Leukemia 2014 ·Clinical Lymphoma Myeloma & Leukemia ·Jitesh D. Kawedia, Michael Rytting	34
11	Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study 2012 ·The Lancet Oncology ·Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen, Elias Jabbour, Partow Kebriaei, Michael Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl, Mary Beth Rios, Jörge E. Cortes, Luis Fayad, (unknown), Sa A. Wang, Richard Champlin, Anjali S. Advani, Susan O’Brien	309
12	Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy 2011 ·Clinical Lymphoma Myeloma & Leukemia ·Stefan Faderl, Deborah A. Thomas, Susan O’Brien, Farhad Ravandi, Guillermo Garcia‐Manero, Gautam Borthakur, Alessandra Ferrajoli, Srđan Verstovšek, (unknown), Michael Rytting, Jennie B. Feliu, Hagop M. Kantarjian	49
13	Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma 2011 ·Cancer ·Maria E. Cabanillas, Hagop Kantarjian, Deborah A. Thomas, Gloria Mattiuzzi, Michael Rytting, Éduardo Bruera, Lianchun Xiao, B. Nebiyou Bekele, Maria Cielo Foudray, Jörge E. Cortes	19
14	Preliminary experience with personalized and targeted therapy for pediatric brain tumors 2011 ·Pediatric Blood & Cancer ·Johannes Wolff, Robert Brown, (unknown), Stefan M. Pfister, Tribhawan S. Vats, Michael Rytting	28
15	Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ all resolution after decitabine therapy 2011 ·Pediatric Blood & Cancer ·(unknown), (unknown), Michael Rytting, Ka Wah Chan	1
16	Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience 2011 ·Journal of Neuro-Oncology ·Johannes Wolff, Michael Rytting, Tribhawan S. Vats, Peter E. Zage, Joann L. Ater, Shiao Y. Woo, John F. Kuttesch, Leena Ketonen, Anita Mahajan	47
17	Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia 2010 ·Cancer ·Michael Rytting, Farhad Ravandi, Elihu H. Estey, Jörge E. Cortes, Stefan Faderl, Guillermo Garcia‐Manero, Sima Jeha, Souzanne Ouzounian, Sherry Pierce, Hagop M. Kantarjian	7
18	Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia 2006 ·Journal of Clinical Oncology ·Sima Jeha, Paul S. Gaynon, Bassem I. Razzouk, Janet Franklin, Richard Kadota, Violet Shen, Lori Luchtman‐Jones, Michael Rytting, Lisa Bomgaars, Susan R. Rheingold, Kim Ritchey, Edythe A. Albano, R.J. Arceci, Stewart Goldman, Timothy J. Griffin, Arnold J. Altman, Bruce G. Gordon, Laurel J. Steinherz, Steven Weitman, Peter G. Steinherz	215
19	Population Pharmacokinetics of Clofarabine, a Second‐Generation Nucleoside Analog, in Pediatric Patients With Acute Leukemia 2004 ·The Journal of Clinical Pharmacology ·Peter L. Bonate, Adam Craig, Paul S. Gaynon, Varsha Gandhi, Sima Jeha, Richard Kadota, Gilbert N. Lam, William Plunkett, Bassem I. Razzouk, Michael Rytting, Peter G. Steinherz, Steve Weitman	35
20	Economic and Resource Utilization Analysis of Outpatient Management of Fever and Neutropenia in Low-Risk Pediatric Patients With Cancer 1999 ·Journal of Pediatric Hematology/Oncology ·Craig A. Mullen, Demetrios Petropoulos, W. Mark Roberts, Michael Rytting, Theodore F. Zipf, Ka Wah Chan, Steven J. Culbert, (unknown), Sima Jeha, John F. Kuttesch, Kenneth V. I. Rolston	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact